Titre : Facteur de croissance endothéliale vasculaire de type A

Facteur de croissance endothéliale vasculaire de type A : Questions médicales fréquentes

Termes MeSH sélectionnés :

Perfusion
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Facteur de croissance endothéliale vasculaire de type A : Questions médicales les plus fréquentes", "headline": "Facteur de croissance endothéliale vasculaire de type A : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Facteur de croissance endothéliale vasculaire de type A : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-02", "dateModified": "2025-02-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Facteur de croissance endothéliale vasculaire de type A" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Facteurs de croissance endothéliale vasculaire", "url": "https://questionsmedicales.fr/mesh/D042442", "about": { "@type": "MedicalCondition", "name": "Facteurs de croissance endothéliale vasculaire", "code": { "@type": "MedicalCode", "code": "D042442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.100.800" } } }, "about": { "@type": "MedicalCondition", "name": "Facteur de croissance endothéliale vasculaire de type A", "alternateName": "Vascular Endothelial Growth Factor A", "code": { "@type": "MedicalCode", "code": "D042461", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Krzysztof Gomułka", "url": "https://questionsmedicales.fr/author/Krzysztof%20Gomu%C5%82ka", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, Wroclaw, Poland." } }, { "@type": "Person", "name": "Gilda Varricchi", "url": "https://questionsmedicales.fr/author/Gilda%20Varricchi", "affiliation": { "@type": "Organization", "name": "Department of Translational Medical Sciences, University of Naples Federico II, 80131, Naples, Italy; Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80131, Naples, Italy; World Allergy Organization (WAO), Center of Excellence, 80131, Naples, Italy; Institute of Experimental Endocrinology and Oncology \"G. Salvatore\" (IEOS), National Research Council (CNR), 80131, Naples, Italy. Electronic address: gildanet@gmail.com." } }, { "@type": "Person", "name": "Anne Lise Ferrara", "url": "https://questionsmedicales.fr/author/Anne%20Lise%20Ferrara", "affiliation": { "@type": "Organization", "name": "Department of Translational Medical Sciences, University of Naples Federico II, 80131, Naples, Italy; World Allergy Organization (WAO), Center of Excellence, 80131, Naples, Italy; Institute of Experimental Endocrinology and Oncology \"G. Salvatore\" (IEOS), National Research Council (CNR), 80131, Naples, Italy." } }, { "@type": "Person", "name": "Stefania Loffredo", "url": "https://questionsmedicales.fr/author/Stefania%20Loffredo", "affiliation": { "@type": "Organization", "name": "Department of Translational Medical Sciences, University of Naples Federico II, 80131, Naples, Italy; Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80131, Naples, Italy; World Allergy Organization (WAO), Center of Excellence, 80131, Naples, Italy; Institute of Experimental Endocrinology and Oncology \"G. Salvatore\" (IEOS), National Research Council (CNR), 80131, Naples, Italy." } }, { "@type": "Person", "name": "Domenico Ribatti", "url": "https://questionsmedicales.fr/author/Domenico%20Ribatti", "affiliation": { "@type": "Organization", "name": "Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy. Electronic address: domenico.ribatti@uniba.it." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "MR Perfusion Imaging for Kidney Disease.", "datePublished": "2023-10-11", "url": "https://questionsmedicales.fr/article/38007278", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.mric.2023.09.004" } }, { "@type": "ScholarlyArticle", "name": "Magnetic Resonance Perfusion Imaging of Prostate.", "datePublished": "2023-10-12", "url": "https://questionsmedicales.fr/article/38007279", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.mric.2023.09.007" } }, { "@type": "ScholarlyArticle", "name": "Arterial Spin Labeling Perfusion Imaging.", "datePublished": "2023-10-08", "url": "https://questionsmedicales.fr/article/38007283", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.mric.2023.08.005" } }, { "@type": "ScholarlyArticle", "name": "Lung preservation: from perfusion to temperature.", "datePublished": "2023-04-12", "url": "https://questionsmedicales.fr/article/37053078", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MOT.0000000000001067" } }, { "@type": "ScholarlyArticle", "name": "Role of Machine Perfusion in Liver Transplantation.", "datePublished": "2023-08-19", "url": "https://questionsmedicales.fr/article/37953040", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.suc.2023.07.001" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Protéines angiogéniques", "item": "https://questionsmedicales.fr/mesh/D042501" }, { "@type": "ListItem", "position": 5, "name": "Facteurs de croissance endothéliale vasculaire", "item": "https://questionsmedicales.fr/mesh/D042442" }, { "@type": "ListItem", "position": 6, "name": "Facteur de croissance endothéliale vasculaire de type A", "item": "https://questionsmedicales.fr/mesh/D042461" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Facteur de croissance endothéliale vasculaire de type A - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Facteur de croissance endothéliale vasculaire de type A", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Facteur de croissance endothéliale vasculaire de type A", "description": "Comment diagnostiquer une surproduction de VEGF-A ?\nQuels examens sont utilisés pour évaluer le VEGF-A ?\nLe dosage du VEGF-A est-il courant ?\nQuels symptômes peuvent indiquer un problème avec le VEGF-A ?\nLe VEGF-A est-il lié à des maladies spécifiques ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Perfusion&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Facteur de croissance endothéliale vasculaire de type A", "description": "Quels symptômes sont liés à une élévation du VEGF-A ?\nLe VEGF-A peut-il causer des problèmes oculaires ?\nComment le VEGF-A affecte-t-il la circulation sanguine ?\nDes symptômes respiratoires peuvent-ils être liés au VEGF-A ?\nLe VEGF-A est-il impliqué dans des douleurs chroniques ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Perfusion&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Facteur de croissance endothéliale vasculaire de type A", "description": "Peut-on prévenir les maladies liées au VEGF-A ?\nL'alimentation influence-t-elle le VEGF-A ?\nLe tabagisme affecte-t-il le VEGF-A ?\nL'exercice physique peut-il réduire le VEGF-A ?\nLe stress a-t-il un impact sur le VEGF-A ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Perfusion&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Facteur de croissance endothéliale vasculaire de type A", "description": "Quels traitements ciblent le VEGF-A ?\nLe traitement du VEGF-A est-il efficace ?\nY a-t-il des effets secondaires des traitements anti-VEGF ?\nLes thérapies géniques peuvent-elles cibler le VEGF-A ?\nLe VEGF-A peut-il être ciblé par des traitements non médicamenteux ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Perfusion&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Facteur de croissance endothéliale vasculaire de type A", "description": "Quelles complications peuvent survenir avec un excès de VEGF-A ?\nLe VEGF-A est-il lié à des complications rétiniennes ?\nDes complications pulmonaires peuvent-elles être causées par le VEGF-A ?\nLe VEGF-A peut-il aggraver des maladies existantes ?\nComment le VEGF-A influence-t-il la cicatrisation ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Perfusion&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Facteur de croissance endothéliale vasculaire de type A", "description": "Quels sont les facteurs de risque pour une élévation du VEGF-A ?\nL'âge influence-t-il les niveaux de VEGF-A ?\nLe diabète est-il un facteur de risque pour le VEGF-A ?\nLe stress psychologique affecte-t-il le VEGF-A ?\nLes maladies inflammatoires sont-elles liées au VEGF-A ?", "url": "https://questionsmedicales.fr/mesh/D042461?mesh_terms=Perfusion&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une surproduction de VEGF-A ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies peuvent mesurer les niveaux de VEGF-A." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer le VEGF-A ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie par résonance magnétique (IRM) et l'échographie peuvent être utilisés." } }, { "@type": "Question", "name": "Le dosage du VEGF-A est-il courant ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est souvent utilisé dans le suivi des cancers et des maladies vasculaires." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec le VEGF-A ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des douleurs, des saignements ou des troubles de la vision peuvent survenir." } }, { "@type": "Question", "name": "Le VEGF-A est-il lié à des maladies spécifiques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est associé à des maladies comme le cancer, la rétinopathie et l'arthrite." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une élévation du VEGF-A ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des douleurs, des œdèmes et des troubles circulatoires." } }, { "@type": "Question", "name": "Le VEGF-A peut-il causer des problèmes oculaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une élévation du VEGF-A peut entraîner des troubles de la vision et des hémorragies rétiniennes." } }, { "@type": "Question", "name": "Comment le VEGF-A affecte-t-il la circulation sanguine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il peut provoquer une angiogenèse excessive, entraînant des problèmes vasculaires." } }, { "@type": "Question", "name": "Des symptômes respiratoires peuvent-ils être liés au VEGF-A ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une inflammation pulmonaire peut survenir en raison d'une surproduction de VEGF-A." } }, { "@type": "Question", "name": "Le VEGF-A est-il impliqué dans des douleurs chroniques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut contribuer à des douleurs chroniques en favorisant l'inflammation." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées au VEGF-A ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain peut réduire le risque de maladies associées au VEGF-A." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le VEGF-A ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut moduler l'expression du VEGF-A." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il le VEGF-A ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter les niveaux de VEGF-A et aggraver les maladies vasculaires." } }, { "@type": "Question", "name": "L'exercice physique peut-il réduire le VEGF-A ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut aider à réguler les niveaux de VEGF-A dans le corps." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur le VEGF-A ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter l'expression du VEGF-A et favoriser l'inflammation." } }, { "@type": "Question", "name": "Quels traitements ciblent le VEGF-A ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les inhibiteurs du VEGF, comme le bevacizumab, sont utilisés pour traiter certains cancers." } }, { "@type": "Question", "name": "Le traitement du VEGF-A est-il efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut réduire la croissance tumorale et améliorer les résultats cliniques." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements anti-VEGF ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme l'hypertension et des saignements peuvent survenir." } }, { "@type": "Question", "name": "Les thérapies géniques peuvent-elles cibler le VEGF-A ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des approches de thérapie génique sont en cours d'étude pour moduler le VEGF-A." } }, { "@type": "Question", "name": "Le VEGF-A peut-il être ciblé par des traitements non médicamenteux ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la radiothérapie peuvent également affecter l'expression du VEGF-A." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec un excès de VEGF-A ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des tumeurs, des hémorragies et des maladies cardiovasculaires peuvent survenir." } }, { "@type": "Question", "name": "Le VEGF-A est-il lié à des complications rétiniennes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une surproduction de VEGF-A peut entraîner des complications comme la néovascularisation." } }, { "@type": "Question", "name": "Des complications pulmonaires peuvent-elles être causées par le VEGF-A ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une élévation du VEGF-A peut contribuer à des maladies pulmonaires comme l'œdème." } }, { "@type": "Question", "name": "Le VEGF-A peut-il aggraver des maladies existantes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut exacerber des maladies comme le diabète et l'hypertension." } }, { "@type": "Question", "name": "Comment le VEGF-A influence-t-il la cicatrisation ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un excès de VEGF-A peut perturber la cicatrisation, entraînant des cicatrices anormales." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour une élévation du VEGF-A ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le tabagisme, l'obésité et des antécédents familiaux de cancer." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux de VEGF-A ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux de VEGF-A peuvent augmenter avec l'âge, augmentant le risque de maladies." } }, { "@type": "Question", "name": "Le diabète est-il un facteur de risque pour le VEGF-A ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut augmenter les niveaux de VEGF-A et favoriser des complications vasculaires." } }, { "@type": "Question", "name": "Le stress psychologique affecte-t-il le VEGF-A ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter l'expression du VEGF-A et aggraver les maladies." } }, { "@type": "Question", "name": "Les maladies inflammatoires sont-elles liées au VEGF-A ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies inflammatoires peuvent augmenter les niveaux de VEGF-A et aggraver les symptômes." } } ] } ] }

Sources (3198 au total)

Lung preservation: from perfusion to temperature.

This article will review the evidence behind elements of the lung preservation process that have remained relatively stable over the past decade as well as summarize recent developments in ex-vivo lun... Ex-vivo lung perfusion is becoming an increasingly well established means to facilitate greater travel distance and allow for continued reassessment of marginal donor lungs. Preliminary reports of the... It is crucial to understand the fundamental principles of organ preservation to ensure optimal lung function posttransplant. Recent advances in the past several years have the potential to challenge s...

Assessment of perfusion deficit with early phases of [

Characteristic features of amyloid-PET (A), tau-PET (T), and FDG-PET (N) can serve for the A/T/N classification of neurodegenerative diseases. Recent studies showed that the early, perfusion-weighted ... We obtained early-phase PET recordings with [... The z-scores of perfusion-weighted images of both tracers showed high correlations across the brain, especially in the frontal and parietal lobes, which were the brain regions with pronounced perfusio... The early perfusion phases of [...

Regional myocardial perfusion imaging in predicting vessel-related outcome: interplay between the perfusion results and angiographic findings.

Despite myocardial perfusion imaging (MPI) by cadmium-zinc-telluride (CZT) single-photon emission computed tomography (SPECT) camera is largely used in the diagnosis and risk stratification of patient... Five hundred and forty-one subjects with suspected or known CAD referred to 99mTc-sestamibi gated CZT-SPECT cardiac imaging and with available angiographic data were studied. Both regional total perfu... Regional myocardial perfusion assessed by the CZT camera demonstrated good reliability in predicting vessel-related events in patients with suspected or known CAD....

Is the optimal Tmax threshold identifying perfusion deficit volumes variable across MR perfusion software packages? A pilot study.

Accurate quantification of ischemic core and ischemic penumbra is mandatory for late-presenting acute ischemic stroke. Substantial differences between MR perfusion software packages have been reported... The HIBISCUS-STROKE cohort includes acute ischemic stroke patients treated by mechanical thrombectomy after MRI triage. Mechanical thrombectomy failure was defined as a modified thrombolysis in cerebr... Eighteen patients were included. Lengthening the threshold from ≥ 6 s to ≥ 10 s led to significantly smaller perfusion deficit volumes for both packages. For package A, Tmax ≥ 6 s and ≥ 8 s moderately... The optimal Tmax threshold for defining the ischemic penumbra appeared to be most accurate at ≥ 6 s for package A and ≥ 10 s for package B. This implies that the widely recommended Tmax threshold ≥ 6 ...

Feasibility of deconvolution-based multiphase CT angiography perfusion maps in acute ischemic stroke: Simulation and concordance with CT perfusion.

Integration of CT perfusion (CTP) with requisite non-contrast CT and CT angiography (CTA) stroke imaging may allow efficient stroke lesion volume measurement. Using surrogate images from CTP, we simul... Patients with acute ischemic stroke who received admission CTP were included in this study. Four CTP images (surrogate mCTA, one pre-contrast and three post-contrast, starting at the arterial peak the... Of 34 included patients, 28 had target mismatch and 6 did not by standard CTP. Accuracy of classifying target mismatch profiles with surrogate mCTA was 79% with respect to that from standard CTP. Mean... Surrogate mCTA ischemic lesion volumes agreed with those from standard CTP and may be an efficient alternative when CTP is not practical....

Normothermic machine perfusion for older transplant recipients.

Elderly patients (≥65 years old) are increasingly undergoing liver transplantation and are more likely to be removed from the waitlist. Normothermic machine perfusion (NMP) holds promise in expanding ... The use of NMP on outcomes in elderly recipients was reviewed using both the UNOS/SRTR database (2016-2022) and institutional data (2018-2020). Characteristics and clinical outcomes were compared betw... Nationally, using the UNOS/SRTR database, we identified 165 elderly recipients from 28 centers who received a liver allograft undergoing NMP and 4270 that underwent traditional cold static storage. NM... NMP may mitigate donor risk factors that are relative contraindications for transplantation in elderly liver recipients, increasing the donor pool. The application of NMP in older recipients should be...